

**AMENDMENTS TO THE CLAIMS**

**This listing of claims will replace all prior versions and listings of claims in the application:**

1.-21. (Canceled)

22. (Currently Amended): A composition to treat hepatic fibrosis ~~in a human~~ in a subject comprising a therapeutically effective amount of unitary doses of viral particles of a recombinant adenoviral vector,

wherein said unitary dose is from about  $10^7$  to about  $10^{14}$  viral particles;

wherein the adenoviral vector ~~comprises an adenoviral vector selected from the group consisting of~~ is the vector contained in ATCC Deposit No. PTA-10532;

and a pharmaceutically compatible carrier.

23. (Canceled)

24. (Currently Amended): A method of treating hepatic fibrosis in a subject ~~fibrotic disorders in a human patient~~, comprising delivering the composition of claim 22 by an intravenous administrative route to the subject a liver; ~~and expressing the therapeutic protein in the liver from the recombinant adenoviral vector of the composition to treat the hepatic fibrotic disorders.~~

25.-34. (Canceled)